Efficacy of pazopanib and sunitinib in advanced axial chordoma: a single reference centre case series

ConclusionThese results on the use of pazopanib and sunitinib in chordoma are promising, with an objective response on sunitinib and a median progression free interval of 8.5  months (range 3–15 months), comparable to that of imatinib, in the pazopanib subgroup. However further research is needed to assess the definite role of VEGFR inhibitors in chordoma.
Source: Clinical Sarcoma Research - Category: Cancer & Oncology Source Type: research